Peregrine Capital Management LLC Collegium Pharmaceutical, Inc Transaction History

Peregrine Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 26, 2024	SELL	$21.16 - $30.8 $2.43 Million - $3.53 Million	-114,658 Reduced 24.97%	344,532 $10.6 Million
Q3 2023 Oct 19, 2023	SELL	$21.23 - $24.28 $416,872 - $476,762	-19,636 Reduced 4.1%	459,190 $10.3 Million
Q2 2023 Jul 26, 2023	SELL	$21.06 - $24.0 $417,451 - $475,728	-19,822 Reduced 3.98%	478,826 $10.3 Million
Q1 2023 Apr 26, 2023	SELL	$23.0 - $29.88 $983,112 - $1.28 Million	-42,744 Reduced 7.9%	498,648 $12 Million
Q4 2022 Jan 10, 2023	SELL	$16.14 - $23.55 $95,048 - $138,685	-5,889 Reduced 1.08%	541,392 $12.6 Million
Q3 2022 Oct 26, 2022	SELL	$15.46 - $20.1 $22,834 - $29,687	-1,477 Reduced 0.27%	547,281 $8.77 Million
Q2 2022 Jul 20, 2022	SELL	$14.22 - $20.88 $112,338 - $164,952	-7,900 Reduced 1.42%	548,758 $9.72 Million
Q1 2022 Apr 27, 2022	SELL	$17.2 - $22.5 $330,945 - $432,922	-19,241 Reduced 3.34%	556,658 $11.3 Million
Q4 2021 Jan 31, 2022	SELL	$17.5 - $21.35 $1.86 Million - $2.27 Million	-106,165 Reduced 15.57%	575,899 $10.8 Million
Q3 2021 Nov 02, 2021	BUY	$17.75 - $25.39 $12.1 Million - $17.3 Million	682,064 New	682,064 $13.5 Million

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.